GIM
AZN icon

Greylin Investment Management’s AstraZeneca AZN Stock Holding History

Greylin Investment Management’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-5,762
Closed -$342K – 69
2013
Q4 		$342K Buy
+5,762
New +$313K 0.08% 60

Other funds holding AZN

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
SCCM
Schafer Cullen Capital Management New York $491M AUM 41.48% 1-Year Est. Return
MAA
Managed Account Advisors Jersey City, New Jersey $121B AUM 7.32% 1-Year Est. Return
EIP
Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
U
UBS Zurich, Switzerland $136B AUM 16.36% 1-Year Est. Return

Greylin Investment Management's AZN Position: Q1 2014 in Review

Greylin Investment Management sold out of AstraZeneca (AZN) in Q1 2014, closing a stake of 5,762 shares — an estimated $342K sold.

Greylin Investment Management first reported a position in AZN in Q4 2013 and held it in 1 quarter. The position peaked at $342K in Q4 2013. 388 funds tracked by Wall St. Rank hold AZN as of Q1 2014.

  • Greylin Investment Management reported no remaining AstraZeneca position as of Q1 2014 after selling out during the quarter.
  • Greylin Investment Management sold 5,762 AstraZeneca shares in Q1 2014, an estimated $342K.
  • Greylin Investment Management first reported a position in AstraZeneca in Q4 2013 and held it in 1 quarter.
  • Greylin Investment Management's AstraZeneca position peaked at $342K in Q4 2013.
  • 388 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2014.

Based on Greylin Investment Management's 13F filing for Q1 2014, filed 12 May 2014.